ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Uncovering the Effect and Mechanism of Rhizoma Corydalis on Myocardial Infarction Through an Integrated Network Pharmacology Approach and Experimental Verification

Li, Jingyan; Wu, Junxuan; Huang, Junying; Cheng, Yuanyuan; Wang, Dawei*; Liu, Zhongqiu*广东省人民医院; 广州大学; 广州中医药大学
Frontiers in Pharmacology2022-7-22DOI: 10.3389/fphar.2022.927488
4被引13阅读
引用收藏
分享

摘要

Background: Myocardial infarction (MI), characterized by reduced blood flow to the heart, is a coronary artery disorder with the highest morbidity and mortality among cardiovascular diseases. Consequently, there is an urgent need to identify effective drugs to treat MI. Rhizoma Corydalis (RC) is the dry tuber of Corydalis yanhusuo W.T. Wang, and is extensively applied in treating MI clinically in China. Its underlying pharmacological mechanism remains unknown. This study aims to clarify the molecular mechanism of RC on MI by utilizing network pharmacology and experimental verification.Methods: Based on network pharmacology, the potential targets of the RC ingredients and MI-related targets were collected from the databases. Furthermore, core targets of RC on MI were identified by the protein-protein interaction (PPI) network and analyzed with Gene Ontology (GO) analysis and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Molecular docking was used to validate the binding affinity between the core targets and the bioactive components. Oxygen-glucose deprivation (OGD) was performed on H9c2 cells to mimic MI in vitro. A Cell Counting Kit-8 assay was used to assess the cardioprotective effect of the active ingredient against OGD. Western blot analysis and RT-qPCR were used to measure the cell apoptosis and inflammation level of H9c2 cells.Results: The network pharmacology obtained 60 bioactive components of RC, 431 potential targets, and 1131 MI-related targets. In total, 126 core targets were screened according to topological analysis. KEGG results showed that RC was closely related to the phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (PKB, also called Akt) signaling pathway. The experimental validation data showed that tetrahydropalmatine (THP) pretreatment preserved cell viability after OGD exposure. THP suppressed cardiomyocyte apoptosis and inflammation induced by OGD, while LY294002 blocked the inhibition effect of THP on OGD-induced H9c2 cell injury. Moreover, the molecular docking results indicated that THP had the strongest binding affinity with Akt over berberine, coptisine, palmatine, and quercetin.Conclusion: THP, the active ingredient of RC, can suppress OGD-induced H9c2 cell injury by activating the PI3K/Akt pathway, which in turn provides a scientific basis for a novel strategy for MI therapy and RC application.

学科与关键词

关键词
Corydalis yanhusuotetrahydropalmatinemyocardial infarctionnetwork pharmacologyapoptosisPI3kAkt signaling pathway
相关
加载中…
  • Network Pharmacology Analysis and Experimental Verification Strategies Reveal the Action Mechanism of Danshen Decoction in Treating Ischemic Cardiomyopathy
    Liu, Mengnan; Yuan, Gang; Luo, Gang; Guo, Xin; Chen, Mingtai; Yang, Huayi; He, Fan; Yang, Tingfu; Zhang, Xinyue; Wu, Qibiao*; Zhou, Hua*; Yang, Sijin*Evidence-based Complementary and Alternative Medicine, 2022, 2022: 7578055.被引 6
  • Protective effect of Qingre Huoxue decoction against myocardial infarction via PI3K/Akt autophagy pathway based on UPLC-MS, network pharmacology, and in vivo evidence
    Jin, Zheng; Zhang, Wenbo; Luo, Yuan; Li, Xiushen; Qing, Lijin; Zuo, Qiang; Fang, Junfeng*; Wu, Wei*PHARMACEUTICAL BIOLOGY, 2021, 59(1): 1607-1618.被引 2
  • Network pharmacology provides a systematic approach to understanding the treatment of ischemic heart diseases with traditional Chinese medicine
    Yang, Hua-Yi; Liu, Mengnan; Luo, Pei*; Yao, Xin-Sheng*; Zhou, Hua*PHYTOMEDICINE, 2022, 104: 154268.被引 24
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Pharmacology
发表日期
2022-07-22
卷期
第 13 卷
页码
927488
DOI
10.3389/fphar.2022.927488
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82104163, 82003826, 81720108033, 81930114]; State Commission of Science Technology of China [2017YFE0119900]; Guangdong Basic and Applied Basic Research Foundation [2019A1515110607, 2021A1515011016, 2020B1515130005]; Guangdong Key Laboratory for translational Cancer research of Chinese Medicine [2018B030322011]; Key-Area Research and Development Program of Guangdong Province [2020B1111100004]; Guangdong Science and Technology Project "Overseas Master" Project [2020A141401022]; Guangzhou Basic Research Program [202102010376]

作者

  • L

    Li, Jingyan (第一作者)

    guangzhou univ chinese med

  • W

    Wu, Junxuan

    guangzhou univ · guangzhou univ chinese med · 2 · guangdong prov hosp

查看全部 6 位作者收起作者
  • H

    Huang, Junying

    guangzhou univ

  • C

    Cheng, Yuanyuan

    guangzhou univ chinese med

  • W

    Wang, Dawei (通讯)

    guangzhou univ

  • L

    Liu, Zhongqiu (通讯)

    guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417